CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Eterna Therapeutics
Company Type: Therapeutic development
Main focus: Developing novel off-the-shelf therapies using mRNA-based technology and induced pluripotent stem cells
Company stage: Pre-clinical
Diseases: Solid cancers
Genome-editing tool: CRISPR-Cas9
Funding stage: Post-IPO Debt
Location: Cambridge, Massachusetts, USA
Website: www.eternatx.com
Pipeline: https://www.eternatx.com/pipeline
Partners:
Eterna Therapeutics is a biotech company focused on the development of off-the-shelf cellular therapies using mRNA-based technology and induced pluripotent stem cells (iPSCs). The company's platform focuses on treating challenging diseases such as solid cancers by enhancing therapeutic cell functionality through genome editing of cells to express critical factors, such as pro-inflammatory cytokines.
